A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Key facts
- Where
- Montreal, Ottawa, and Toronto, CanadaSee the 4 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Source: NCT07033494, who can take part
Where in Canada
- Clinique Mémoire de Montreal (Site 2000)Montreal, CanadaTaking people
- Ottawa Memory Clinic (Site 2001)Ottawa, CanadaTaking people
- Sunnybrook Research Institute (Site 2003)Toronto, CanadaTaking people
- Toronto Western Hospital (Site 2004)Toronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Merck Sharp & Dohme LLC
- Trial code
- NCT07033494EU 2024-519190-19-00
- Record updated
- 20 October 2026
- Original description
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD.Read full original descriptionShow less
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants With Early Alzheimer's Disease
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD.
The goals of the study are to learn:
* If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it
Inclusion: The main inclusion criteria include but are not limited to the following:; Has mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD); Has a designated study partner who can fulfill the requirements of this study; If on an approved AD therapy for symptomatic AD, the dosing regimen must have been stable for 3 months prior to screening.
Exclusion: Has major medical illness or unstable medical condition within 3 months before screening; Has any immunological disease, which is not adequately controlled, or which requires treatment with biologics and/or immunosuppressants during the study; Has a known history of stroke or cerebrovascular disease; Has diagnosis of a clinically relevant central nervous system disease other than AD or other condition that negatively impacts cognition or cognitive status chronically; Has structural brain disease; Has a history of seizures or epilepsy within 5 years before screening; Has any other major central nervous system trauma, or infections that affect brain function; Has a bleeding disorder that is not under adequate control; Has a history of malignancy occurring within 5 years of screening; Has liver disease; Has a severe, acute, or chronic medical or psychiatric condition or laboratory abnormality; Has a risk factor for corrected QT interval (QTc) prolongation; The main exclusion criteria include but are not limited to the following:; Is unwilling or unable to undergo computed tomography (CT), positron emission tomography (PET), or magnetic resonance imaging (MRI) scan; Resides in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision.